Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RARA | P10276 | 8/20 | 0.45 |
| ▸ | RARB | P10826 | 8/20 | 0.45 |
| ▸ | RARG | P13631 | 8/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 5/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047272 | 1.00 | MAPT (0.47) | MAPTCYP3A4TP53BLMSMN1; SMN2 | |
| SCHEMBL5048367 | 0.92 | SMN1; SMN2 (0.47) | MAPTCYP3A4TP53BLMSMN1; SMN2 | |
| SCHEMBL5048368 | 0.92 | SMN1; SMN2 (0.47) | MAPTCYP3A4TP53BLMSMN1; SMN2 | |
| SCHEMBL5043978 | 0.90 | MAPT (0.45) | MAPTCYP3A4TP53BLMSMN1; SMN2 | |
| SCHEMBL5043982 | 0.90 | MAPT (0.45) | MAPTCYP3A4TP53BLMSMN1; SMN2 | |
| SCHEMBL5050748 | 0.83 | MAPT (0.47) | MAPTCYP3A4TP53BLMSMN1; SMN2 | |
| SCHEMBL5050750 | 0.83 | MAPT (0.47) | MAPTCYP3A4TP53BLMSMN1; SMN2 | |
| SCHEMBL5048397 | 0.83 | RARB (0.58) | CYP3A4TP53BLMSMN1; SMN2HSD17B10 | |
| SCHEMBL5048391 | 0.83 | RARB (0.58) | CYP3A4TP53BLMSMN1; SMN2HSD17B10 | |
| SCHEMBL5048392 | 0.83 | RARB (0.58) | CYP3A4TP53BLMSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | claimed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | claimed |
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | MAPT 4731/4885CYP3A4 2257/4885TP53 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.